Venetoclax Combined With Azacitidine for Consolidation Therapy in AML
Recruiting
Phase 2
Interventional Study
Acute Myeloid Leukemia
Consolidation Therapy
Venentoclax
High Risk
Hematopoietic Stem Cell Transplant (HSCT)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 216 (estimated)
- Sponsor
- The First Affiliated Hospital of Soochow University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to compare the efficacy and safety of a venetoclax-based consolidation therapy versus conventional consolidation chemotherapy in newly diagnosed adult patients with high-risk acute myeloid leukemia (AML) who have achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi) after induction therapy with venetoclax and azacitidine and are planne…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of AML confirmed by bone marrow morphology, flow cytometry, and molecular genetics, meeting WHO 2022 classification criteria;
* Age ≥ 18 years;
* Classified as high-risk according to the European LeukemiaNet (ELN) prognostic risk stratification for AML, including AML…
Contacts